Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

This FDA News Month in Review provides a round-up of regulatory decisions from January 2026.

New data presented at EHSF in Malta boasts a reduced proportion of patients with severe HS at 3 years.

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

The resubmission follows a prior Complete Response Letter (CRL) that identified chemistry, manufacturing, and control (CMC) issues.

An audio recap of the top 5 stories in healthcare news from the week of 01/18-01/24.

GRI-0621 shows promise as a safe, effective treatment for idiopathic pulmonary fibrosis, improving biomarkers and lung function in a Phase 2a trial.

New guidelines on biologic management for severe asthma provide essential recommendations for optimizing treatment choices among clinicians.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Higher accuracy lung biopsy could make a strong impact on lung cancer diagnoses and outcomes.

Experts discussed how biologics revolutionize asthma and COPD management, emphasizing personalized treatment strategies and proactive care.

Despite an OTC approval in 2023, recent data highlights a carry rate of only 10% in the general population.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

December 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

Pulmonary arterial hypertension treatment continues to evolve with new therapies and strategies.

The Q4 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

The pulmonology year in review highlights FDA approvals and pivotal data readouts.

The designation follows positive phase 2b data and FDA alignment on a phase 3 trial.

An audio recap of the top 5 stories in healthcare news from the week of 12/28-1/3.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

The COPD year in review highlights FDA approvals, data, and advances in 2025.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

November 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

PR was seen to reduce FeNO, a biomarker of type 2 inflammation, in a new study.

However, a related editorial from University of Rome was quick to point out possibly sizable placebo effects in the trial.

COPD management evolves with biologics, emphasizing personalized care and treatable traits to improve patient outcomes and address ongoing challenges.

COPD management evolves with targeted biologic therapies, enhancing treatment precision and improving patient outcomes in respiratory care.

Acute kidney injury mortality rises in wealthier nations, highlighting urgent need for targeted prevention strategies.

Sibeprenlimab shows promising results in reducing proteinuria and improving kidney health in IgA nephropathy.

A recent study reveals that younger patients with glomerular disease face a higher lifetime risk of kidney failure despite similar progression rates.